Posted: 10 October 2025
Nutromics has announced a major milestone in wearable diagnostics, unveiling the world’s first real-time, continuous in vivo data for two antibiotics—vancomycin and tobramycin—measured simultaneously on a single device. The breakthrough was presented at the International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) in Singapore.
The study, conducted in rats, demonstrated Nutromics’ platform could continuously track multiple drug levels in real time using its Lab-on-a-Patch® technology. The microneedle-based device enabled the simultaneous monitoring of vancomycin and tobramycin, both frontline antibiotics used to treat severe infections such as sepsis and MRSA. The company said the innovation could help clinicians optimise dosing to improve patient safety and reduce antimicrobial resistance.
“Our goal is to start providing real-time molecular data in critical care settings,” said Chief Operating Officer Hitesh Mehta. “Clinicians often tell us they are currently flying blind, relying on delayed, point-in-time data. Demonstrating multiplexing proves this technology is a true platform and affirms our larger goal: delivering real-time data for drugs and biomarkers to transform care across hospital and community settings.”
To achieve dual detection, Nutromics scientists used microneedles coated in synthetic DNA-based sensors, known as aptamers, each selective for a specific antibiotic. The aptamers responded independently and accurately, confirming both sensitivity and specificity.
Lead scientist Julian Gerson said the achievement marked a major advance for biosensor technology: “We are the first to show multiplexed measurement of antibiotics in vivo—something existing technologies have not achieved. This demonstrates Nutromics’ ability to translate aptamer sensors from the lab to the body with high fidelity.”
The company recently secured A$7.5 million in new funding and has completed first-in-human studies. Clinical trials in Australian hospital ICUs are underway, with U.S. trials planned for 2026.
Find out more here.
